Exclusive: The curious case of the BioNTech priority review voucher
Earlier this week, the FDA fully approved Moderna’s Covid-19 vaccine, and with that approval, the company was awarded what is almost certainly a lucrative priority review voucher.
The vouchers can be used for a priority review of a new drug, offering a short cut to an FDA decision, or can be sold on the open market — for upwards of $100 million.
The PRV for Moderna was issued by the FDA under its material threat medical countermeasure PRV program, and that program has allowed FDA to provide a PRV for all fully approved products used to treat or prevent Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
